Canada Must Shift VC Mindset to Revitalize Life Sciences Sector

Canada’s renowned strength in life sciences research is facing significant challenges in commercializing its discoveries. Sir Michael Houghton, a Nobel Laureate, highlighted these issues during a discussion with Chris Hogg, CEO and Executive Editor of Digital Journal, at the recent Life Sciences Week in Edmonton. He emphasized the urgent need for a shift in venture capital (VC) investment strategies to bridge the critical gap in early-stage development.

The conversation set the tone for the week’s events, which brought together researchers, entrepreneurs, and health leaders to explore Alberta’s progress in the life sciences sector. Houghton, speaking virtually from California, pointed out a persistent obstacle in Canada’s ability to transform scientific breakthroughs into market-ready products.

“Canada has strong science at the basic level,” Houghton stated. “But the ability to develop those inventions into products really has not been in Canada, traditionally.” He referred to this gap as the “Valley of Death,” a term used across innovation sectors to describe the period between laboratory breakthroughs and the early development necessary for commercialization. This stage is often fraught with risks and typically lacks the necessary infrastructure, capital, and regulatory expertise.

Houghton noted that the exodus of pharmaceutical companies from Canada has left a void in the market, diminishing pathways for translating academic discoveries into commercial applications. “There are no so-called knowledge users and receptors,” he explained, which has pushed many Canadian researchers to seek opportunities elsewhere, particularly in the United States and Western Europe.

Investment hesitancy is a significant barrier to growth in this sector. Houghton pointed out that while Canada boasts a robust oil and gas industry, this has led investors to perceive it as a safer bet compared to high-risk biotech ventures. “We know that these high-risk industries in biotech pay off enormously. Not just for the investors, but for the national economies,” he said, underscoring the need to increase venture capital in Alberta and across Canada.

The current investment climate is causing a detrimental export of Canadian intellectual property (IP) and economic value. To counter this, Houghton advocates for strengthening infrastructure that supports early-stage development. As the Chief Scientific Officer of Applied Pharmaceutical Innovation (API), he believes that enhancing the conditions for biotech investment is essential.

API is actively working on developing large-scale manufacturing capabilities in Edmonton, including facilities for small molecule drugs and fill-finish processes. Houghton highlighted API’s collaboration with researchers at the University of Alberta and the University of British Columbia on a potential RNA vaccine for hepatitis C, which aims to improve safety through next-generation lipids. This project exemplifies the integration of discovery, development, and manufacturing within Canada, which Houghton argues is vital for maintaining a robust innovation pipeline.

Public policy also plays a crucial role in facilitating early-stage innovation. Houghton acknowledged the funding support from Alberta and federal governments but urged policymakers to examine successful models from other countries. He cited the U.S. Small Business Innovation Research (SBIR) program, which provides federal grants to help researchers and small companies navigate the early stages of product development.

“Many people in the U.S. consider [SBIR] to be the main driver of U.S. innovation and products and the economy,” he noted. Houghton stressed that Canada must do more to assist its innovators in crossing the Valley of Death.

As the discussion shifted towards future momentum, Houghton expressed optimism for a significant success story emerging from Alberta within the next two to three years. “What we really need in biotech is a big success,” he stated, suggesting that one major achievement could inspire greater investor confidence and encourage a culture of repeated success in the sector.

The challenges facing the life sciences industry in Canada are well known, but whether the country will view them as structural limitations or solvable challenges remains to be seen. Houghton’s insights underscore a pivotal choice that could determine whether Canadian life sciences continue to be a source of scientific achievement or evolve into a foundation for global impact.

Digital Journal serves as the official media partner for Life Sciences Week, helping to shed light on these critical discussions and the future of innovation in Canada.